← Back to Search

FTT PET/CT Imaging for Breast Cancer

Phase 1
Waitlist Available
Led By Elizabeth McDonald, MD
Research Sponsored by Abramson Cancer Center at Penn Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Known or suspected (BIRADS 5 on imaging) primary breast cancer
At least one breast lesion one breast lesion that is 1 cm or greater in size by standard imaging (e.g. mammography, ultrasound or breast MRI). Only one type of imaging is required to show a lesion of 1 cm or greater in order for the patient to be eligible to participate in this study. Patients that have a prior diagnosis of primary breast cancer in the opposite breast can be included.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether FTT PET/CT can help predict how well a patient will respond to breast cancer surgery or neoadjuvant therapy.

Who is the study for?
This trial is for adults over 18 with suspected or confirmed breast cancer, showing a lesion of at least 1 cm on imaging. Participants must be willing to provide tissue samples and consent to research use. It's not suitable for those who can't tolerate imaging procedures, have conditions compromising safety/participation, or are pregnant/breastfeeding.
What is being tested?
[18F]FluorThanatrace (FTT) PET/CT scans are being tested in up to 30 participants before surgery or therapy for breast cancer. The study may include a second scan after starting therapy to correlate FTT uptake with pathology and treatment response.
What are the potential side effects?
While the description doesn't list specific side effects of [18F]FluorThanatrace, typical PET/CT scan risks include exposure to radiation, potential allergic reactions to tracers, discomfort from lying still during the procedure, and anxiety.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am diagnosed or highly suspected to have primary breast cancer.
Select...
I have a breast lesion that is at least 1 cm large, confirmed by imaging.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor
418 Previous Clinical Trials
464,822 Total Patients Enrolled
46 Trials studying Breast Cancer
360,857 Patients Enrolled for Breast Cancer
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
108,455 Total Patients Enrolled
40 Trials studying Breast Cancer
35,283 Patients Enrolled for Breast Cancer
Elizabeth McDonald, MDPrincipal InvestigatorAbramson Cancer Center at Penn Medicine

Media Library

[18F]FluorThanatrace Clinical Trial Eligibility Overview. Trial Name: NCT03083288 — Phase 1
Breast Cancer Research Study Groups: Single Arm
Breast Cancer Clinical Trial 2023: [18F]FluorThanatrace Highlights & Side Effects. Trial Name: NCT03083288 — Phase 1
[18F]FluorThanatrace 2023 Treatment Timeline for Medical Study. Trial Name: NCT03083288 — Phase 1
~4 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top